Phosphodiesterase 3 Inhibitor [EPC]
Semantic Scholar uses AI to extract papers important to this topic.
Atrial fibrillation (AF) represents the most common arrhythmia encountered in cardiology department. The purpose of… Expand Despite the availability of effective antiulcer medications, their suboptimal safety profile ignites the search for alternative… Expand BACKGROUND
Cilostazol, a phosphodiesterase 3 inhibitor (PDE3I), is a platelet aggregation inhibitor and vasodilator that is… Expand Phosphodiesterase 3 inhibitors have been used successfully in pediatric patients with acute or chronic myocardial dysfunction… Expand OBJECTIVE: To assess the efficacy and safety of cilostazol on the progression and regression of symptomatic intracranial artery… Expand OBJECTIVE
To investigate whether bladder dysfunction after bladder outlet obstruction (BOO) could be altered by treatment with… Expand MOTS CLÉS Association d’antiagrégants plaquettaires ; Maladie thrombotique More than 22 million Americans are estimated to take… Expand BACKGROUND
Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular… Expand The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… Expand 1 This study was designed to investigate the role of rat phosphodiesterase 3 (RPDE3) in regulation of liver metabolism in sepsis… Expand